"Medical Cannabis": Advising Patients While Navigating Medical Ethics and Limited Evidence
- PMID: 40624323
- DOI: 10.1007/s11606-025-09680-7
"Medical Cannabis": Advising Patients While Navigating Medical Ethics and Limited Evidence
Abstract
Cannabis is increasingly legalized in more areas of the USA and marketed under the misnomer "medical cannabis." Yet, there are no official dosing guidelines or approved medical uses for plant cannabis by the Food and Drug Administration. Due to significant federal barriers, research on efficacy, safety, and adverse effects of cannabis is limited. Patients are interested in cannabis as potential treatment of medical issues and/or symptoms and clinicians should include a discussion of the risks of cannabis consumption. However, many risks are not yet known, and clinicians might be unaware of the emerging literature. This perspective summarizes the potential harms of cannabis, including the risk of cannabis use disorder, while providing a framework grounded in principles of medical ethics to educate patients on cannabis.
© 2025. The Author(s), under exclusive licence to Society of General Internal Medicine.
Conflict of interest statement
Declarations:. Ethics Approval and Consent to Participate:: Not applicable Conflict of Interest:: MRL has been a scientific consultant in the last three years (unrelated to this paper) for Berkshire Biomedical, Braeburn, Camurus, and Journey Colab. SB has previously been a scientific consultant to Canopy Growth Corporation (unrelated to this paper). The other authors report no conflicts of interest.
References
-
- American Society of Addiction Medicine. Public policy statement on cannabis. Available at https://www.asam.org/docs/default-source/public-policy-statements/2020-p... Accessed on 10 Feb 2023.
-
- Freckelton I. Children as voices and images for medicinal cannabis law reform. Monash Bioeth Rev. 2021;39: 4–25.
-
- Team Kentucky Office of Medical Cannabis. Kentucky medical cannabis program regulations. Available at https://kymedcan.ky.gov/laws-and-regulations/Pages/Regulations.aspx . Accessed on 8 Oct 2024.
-
- United States Drug Enforcement Administration. Drug scheduling. Available at https://www.dea.gov/drug-information/drug-scheduling . Accessed on 8 Oct 2024.
-
- Food and Drug Enforcement Administration. Full prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf . Accessed on 17 Feb 2025.
Publication types
LinkOut - more resources
Full Text Sources